View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 5, 2011

MedImmune Loses Drug-Screening Patents

MedImmune, a subsidiary of global pharmaceutical company AstraZeneca, has lost the patent rights to a biotechnology screening technique used in drugs such as Roche's eye treatment drug Lucentis (ranibizumab). Novartis, Roche's European marketing partner, sued MedImmune in April in a bid

By cms admin

MedImmune, a subsidiary of global pharmaceutical company AstraZeneca, has lost the patent rights to a biotechnology screening technique used in drugs such as Roche’s eye treatment drug Lucentis (ranibizumab).

Novartis, Roche’s European marketing partner, sued MedImmune in April in a bid to revoke an extension on patent protection for a manufacturing process known as ‘phage display’.

The High Court in London, UK, ruled that MedImmune’s two patents were invalid, meaning that Roche and Novartis can now free manufacture the drug without paying royalties to MedImmune, reports the Financial Times.

A judgment in favour of MedImmune would have dealt a blow to Lucentis, which last year generated sales of $1.53 billion for Switzerland-based Novartis.

AstraZeneca has said it will appeal for the patents, which it sees as valid.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology